Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
Status:
Completed
Trial end date:
2017-09-15
Target enrollment:
Participant gender:
Summary
This study will be conducted to find out how well a patient of rheumatoid arthritis (RA) will
respond to disease-modifying antirheumatic drugs (DMARDs). RA is a chronic inflammatory
arthritis, which leads to joint damage & disability if not treated properly. A DMARD is used
to treat RA that slows down or prevents joint damage, as opposed to just relieve pain or
inflammation by painkillers. The study will be conducted at the Department of Clinical
Immunology, JIPMER (Jawaharlal Institute of Postgraduate Medical Education & Research).
Patients will receive either a single DMARD (Methotrexate) or combination DMARDs therapy
(Methotrexate + Leflunomide + Hydroxychloroquine). During treatment course, routine blood
investigations will be carried out to monitor treatment response and side effects.
Phase:
Phase 4
Details
Lead Sponsor:
Jawaharlal Institute of Postgraduate Medical Education & Research